Skip to main content

Conditions influencing the in vitro antifungal activity of lactoferrin combined with antimycotics against clinical isolates of Candida: Impact on the development of buccal preparations of lactoferrin

Buy Article:

$43.00 plus tax (Refund Policy)

Lactoferrin, an iron-binding glycoprotein, is a potential agent for the treatment of oropharyngeal Candidiasis. The aim of the present study was to test the capability of lactoferrin, combined or not combined with conventional antifungal agents, to inhibit the growth of different Candida species under various experimental conditions to be of guidance in the development of a suitable pharmaceutical formulation containing lactoferrin. The anti-Candida activities of lactoferrin were considerably higher using RPMI instead of SLM as assay medium. They were moreover increased by raising the medium pH from 5.6 to 7.5. With the ‘standard’ antifungal agent fluconazole similar results were found as for lactoferrin, but the medium type and pH did not affect MIC values of amphotericin B. The addition of saliva to medium did not reduce the antifungal activities of the individual compounds. Synergistic inhibitory effects on Candida growth were found for combinations of lactoferrin and fluconazole or amphotericin B, irrespective of the medium type and pH, or the addition of saliva. This indicates that for treatment of oral Candidiasis a formulation containing lactoferrin seems appropriate; results may be optimized if the formulation is provided with buffer capacity to attain pH 7.5 in the mucosal fluid. The synergistic effects between lactoferrin and ‘standard’ antifungals indicate that combinations should be considered in such a formulation.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Candida; Lactoferrin; antifungal agents; fluconazole; pH; saliva

Document Type: Research Article

Affiliations: 1: Groningen University Institute for Drug Exploration (GUIDE), Dept. of Pharmacokinetics and Drug Delivery, University Center for Pharmacy, Groningen, 2: Numico Research B.V., Wageningen, 3: University Hospital Groningen, Section of Medical Microbiology, Groningen, The Netherlands

Publication date: 2002-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more